Home » International News » 2011 » August » August 29, 2011

BIOTRONIK Announces European Market Approval of Selectra: Advanced New Telescopic CRT Lead Delivery System

August 29, 2011 - Brelin, Germany

BIOTRONIK, a leading manufacturer of implantable cardiac devices and pioneer of wireless remote monitoring technologies, today announced the European market approval of the Selectra left ventricular lead delivery system.

Selectra: Advanced New Telescopic CRT Lead Delivery System (Photo: Business Wire)

Selectra: Advanced New Telescopic CRT Lead Delivery System (Photo: Business Wire)

Selectra, which represents a significant advancement in lead placement systems for cardiac resynchronization therapy (CRT) devices, is the first telescopic delivery system for direct delivery of low-profile left ventricular leads to incorporate a slittable hemostatic valve that reduces the complexity involved during a lead implant as well as the likelihood of moving the left ventricular lead as the sheath is removed.

“BIOTRONIK spent considerable time understanding electrophysiologists’ needs and examining the challenges they face with current lead delivery systems. It is this intensive insight that has formed the basis for engineering Selectra’s advanced design,” commented Marlou Janssen, Vice President of Global Marketing & Sales.

“In a challenging CRT case,” Janssen continues, “there are two concerns regarding lead delivery. First, you have to ensure that you’ve achieved optimal lead placement, then you must be able to remove the catheter without altering the position of the lead. The Selectra system appears to be very promising in terms of balancing flexibility and firmness, which will allow easy access to the coronary sinus. Slitting the Selectra sheaths is simple and straightforward.”

The device’s unique handle design has an integrated side port, allowing for maximum flexibility and one-handed manipulation, which results in ultimate convenience during even the most challenging implantations. The superior shaft design, with its balanced stiffness segmentations, provides optimal torque transmission while preventing kinking of the catheter. The short soft tip design minimizes the risk for dissections during cannulation of the coronary sinus and prolapse during lead maneuvering.

Selectra also incorporates a streamlined, fully integrated hub to minimize handling complexity and maximize the working length of the sheath during implant. Its hydrophilic inner coating reduces friction, thereby increasing the free movement of coronary sinus leads or the subselector catheters during introduction and providing lead dislodgment prevention during the removal of the catheter system.

The Selectra lead delivery system complements BIOTRONIK’s broad CRT portfolio, which includes Corox OTW bipolar (BP) leads and premium Lumax CRT-D devices. In January 2011, BIOTRONIK launched the newest member of the Corox BP lead family, the Corox OTW-L BP, which offers a third unique design with excellent stability and handling characteristics. These exceptional advances, together with new 4 F Sentus OTW UP coronary sinus lead, deliver a complete system for telescopic delivery of coronary sinus leads.


As one of the world’s leading manufacturers of cardiovascular medical devices, with several million devices implanted, BIOTRONIK is represented in over 100 countries by its global workforce of more than 5,600 employees. Known for having its finger on the pulse of the medical community, BIOTRONIK assesses the challenges physicians face and provides the best solutions for all phases of patient care, ranging from diagnosis to treatment to patient management. Quality, innovation and reliability define BIOTRONIK and its growing success—and deliver confidence and peace of mind to physicians and their patients worldwide.

For more information: visit

Upon publication, please provide us with a copy.

Photos/Multimedia Gallery Available:


CONTACTS : BIOTRONIK SE & Co. KG Sandy Hathaway Senior Director, Global Communications +49 (0) 30 68905 1602

Source: Business Wire India


Comment on this story